Charles River Laboratories International, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CRL research report →
Range $219 – $388
Price Chart
About the company
Charles River Laboratories International, Inc. operates as a contract research organization (CRO), providing essential preclinical services to the pharmaceutical and biotechnology industries. Its core business revolves around assisting clients with drug discovery, non-clinical development, and thorough safety testing, with its services extending globally across the United States, Europe, Canada, and the Asia Pacific region.
- CEO
- Birgit Girshick
- IPO
- 2000
- Employees
- 19,000
- HQ
- Wilmington, MA, US
Get TickerSpark's AI analysis on CRL
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $15.06B
- P/E
- 308.16
- Fwd P/E
- 27.41
- PEG
- -3.46
- P/S
- 3.79
- P/B
- 4.66
- EV/EBITDA
- 60.40
- Div Yield
- 0.00%
- Gross Margin
- 32.90%
- Op Margin
- 14.15%
- Net Margin
- 1.01%
- ROE
- 1.32%
- ROIC
- -3.76%
Latest fiscal year · YoY change
- Revenue
- $4.02B-0.9%
- Gross Profit
- $1.23B-8.0%
- Op Income
- $507.84M
- Net Income
- $-144,338,000-1501.7%
- EPS
- $-2.91-1555.0%
- OCF Growth
- +0.4%
- FCF Growth
- +3.4%
- 52W High
- $379.63
- 52W Low
- $146.20
- 50D MA
- $315.23
- 200D MA
- $230.22
- Beta
- 1.34
- RSI (14)
- 43
- Avg Volume
- 1.03M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Charles River delivered a stronger-than-expected third quarter, with broad-based demand improvement, margin expansion, and a raised full-year outlook.· November 4, 2026
- Revenue and non-GAAP EPS both beat prior outlook, with organic revenue up 4.7% and non-GAAP EPS of $3.09, up 27.2% year over year.
- DSA momentum improved: revenue rose 5.9% organically, net bookings increased 32% to $652 million, and net book-to-bill was 1.09x for the fourth straight quarter above 1x.
- Manufacturing rebounded strongly, with 7.4% organic growth and operating margin of 38.6%, helped by the CDMO divestiture and higher volume.
- Management raised full-year 2026 guidance for organic revenue to at least 1.5% growth and non-GAAP EPS to $11.35-$11.55.
- RMS remained a soft spot, with organic revenue down 0.6% as North America and government/academic demand stayed pressured, partially offset by China and government contract awards.
Third-quarter revenue increased 4.7% year over year to the highest level since the second quarter of 2023. Organic revenue also increased 4.7%, and non-GAAP EPS was $3.09, up 27.2% year over year. Non-GAAP operating margin improved 330 basis points year over year and 250 basis points sequentially to 23%. By segment, DSA revenue was $596 million, up 5.9% organically; manufacturing revenue was $179 million, up 7.4% organically; and RMS revenue was $208 million, down 0.6% organically. DSA net bookings increased 32% year over year to $652 million, backlog rose to $2.03 billion, and net book-to-bill was 1.09x. Manufacturing operating margin was 38.6%, DSA operating margin was 26.8%, and RMS operating margin was 24.4%. Free cash flow was $207 million, CapEx was $47 million, and gross/net leverage improved to 2.3x. Management raised full-year reported revenue guidance to a decline of 1.5%-2%, raised organic revenue growth guidance to at least 1.5%, and increased non-GAAP EPS guidance to $11.35-$11.55. For Q4, management expects DSA and manufacturing organic growth to remain at mid-single-digit and high single-digit rates, respectively, with continued sequential margin improvement of about 150 basis points and non-GAAP EPS growth of approximately 30%-40% year over year.
Birgit Girshick said the quarter showed clear progress on the company’s Pathway to Purpose strategy, with improving biopharma demand, better execution, and early benefits from modernization initiatives. She emphasized that the business is becoming more agile and client-centric, with stronger proposals, bookings, and backlog supporting gradual improvement into 2027 and a later move toward the 5%-7% long-term growth target. Her tone was constructive and confident, while noting that pricing power and some end markets still need time to recover.
Glenn Coleman highlighted that organic revenue of 4.7% was the strongest growth in three years and that non-GAAP EPS of $3.09 exceeded the prior outlook of $2.90-$3.00. He cited margin expansion to 23%, DSA margin of 26.8%, manufacturing margin of 38.6%, and RMS margin of 24.4%, plus free cash flow of $207 million and leverage of 2.3x. He also said CapEx remains expected at about $200 million, free cash flow at $400 million-$420 million, net interest expense at the high end of $103 million-$108 million, and the non-GAAP tax rate at about 23%.
Analysts focused on the pace of 2027 improvement, AI’s impact on bookings, pricing, NHP supply, and whether DSA growth can sustain momentum. Management said AI is already helping sector interest and funding, but it is hard to separate AI-driven demand from broader biotech improvement; they also said AI-native programs tend to increase validation work, but it is too early to quantify revenue impact. On pricing, management said DSA discounting is only beginning to narrow, with no Q3 booking impact yet, and that meaningful revenue benefit likely would not show until at least the second half of 2027. They also said about 80% of estimated NHP usage is covered by internal supply, with enough supply to support long-range targets.
The quarter showed that demand is improving across key businesses, especially DSA and manufacturing, with bookings, proposals, backlog, and revenue all trending better. Management also sounded confident that modernization, cost savings, and better pricing discipline can drive further margin expansion, while AI and biologics complexity could add more regulated work over time.
RMS is still under pressure from softer North American demand and weak academic/government funding, and management said it may take time to fully recover. DSA pricing has not yet flowed through to revenue, and management cautioned that the benefit may not be visible until the second half of 2027, while DSA growth next year still depends on timing, mix, and resource availability.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 98.9%
- Shares Outstanding
- 47.92M
- Float Shares
- 47.38M
of shares held by institutions
587 13F filers
Buy/sell ratio 0.50. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Congressional trading
Senate and House stock disclosures for CRL, newest first.
| Member | Type | Traded | |
|---|---|---|---|
| Jefferson ShreveHouse · IN06 | Buy | May 8, 25 | Filing → |
| Jefferson ShreveHouse · IN06 | Sell | May 12, 25 | Filing → |
| Robert P. BresnahanHouse · PA08 | Sell | May 15, 25 | Filing → |
| Robert P. BresnahanHouse · PA08 | Buy | Apr 8, 25 | Filing → |
| Julie JohnsonHouse · TX32 | Buy | Jan 15, 25 | Filing → |
| Ro KhannaHouse · CA17 | Buy | Nov 15, 24 | Filing → |
| Ro KhannaHouse · CA17 | Sell | Nov 3, 23 | Filing → |
| Ro KhannaHouse · CA17 | Buy | Oct 2, 23 | Filing → |
| Lois FrankelHouse · FL22 | Sell | Sep 8, 23 | Filing → |
| Ro KhannaHouse · CA17 | Sell | Aug 29, 23 | Filing → |
| Ro KhannaHouse · CA17 | Buy | May 19, 23 | Filing → |
| Ro KhannaHouse · CA17 | Buy | May 23, 23 | Filing → |
| Lois FrankelHouse · FL22 | Buy | Apr 25, 23 | Filing → |
| Zoe LofgrenHouse · CA19 | Sell | Aug 25, 22 | Filing → |
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Fmr LLC | 5.97M | ▲ 1.73M |
| Vanguard Group Inc | 5.89M | ▲ 47.43K |
| Blackrock, Inc. | 3.78M | ▼ 21.18K |
| Vanguard Capital Management LLC | 3.13M | ▼ 21.46K |
| Price T Rowe Associates Inc | 3.01M | ▲ 1.50M |
| Vanguard Portfolio Management LLC | 2.19M | ▼ 21.82K |
| State Street Corp | 1.87M | ▲ 9.59K |
| Invesco Ltd. | 1.85M | ▼ 1.13M |
| Harris Associates L P | 1.41M | ▼ 830.81K |
| Geode Capital Management, LLC | 1.30M | ▼ 5.56K |
| Ariel Investments, LLC | 1.19M | ▼ 312.84K |
| Earnest Partners LLC | 1.09M | ▼ 33.04K |
Held by 1,073 ETFs
Biggest fund positions in CRL by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 6, 26 | Knell Michael Gunnar | other | 649 |
| Oct 22, 26 | FOSTER JAMES C | other | 24,042 |
| Oct 22, 26 | FOSTER JAMES C | sell | 24,042 |
| Oct 22, 26 | FOSTER JAMES C | other | 24,042 |
| Oct 21, 26 | Parisotto Shannon M | other | 2,156 |
| Oct 21, 26 | Parisotto Shannon M | sell | 2,156 |
| Oct 21, 26 | Parisotto Shannon M | other | 2,156 |
| Oct 5, 26 | Parisotto Shannon M | other | 981 |
| Oct 5, 26 | Parisotto Shannon M | sell | 981 |
| Oct 5, 26 | Parisotto Shannon M | other | 981 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our CRL coverage
Recent articles, reports, and earnings notes.
Want a deeper read on CRL?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
Charles River Stock Surges 102.3% in a Year: What's Fueling the Drive?
zacks.com · Nov 20
Should You Continue to Hold Charles River Stock in Your Portfolio?
zacks.com · Nov 18
Fifth Third Bancorp Purchases 4,299 Shares of Charles River Laboratories International, Inc. $CRL
defenseworld.net · Nov 17
Ariel Small Cap Value Concentrated Q3 2026 Portfolio Activity
seekingalpha.com · Nov 17
Charles River Laboratories to Present at Jefferies Global Healthcare Conference
businesswire.com · Nov 16
Alpha Teknova (NASDAQ:TKNO) versus Charles River Laboratories International (NYSE:CRL) Critical Analysis
defenseworld.net · Nov 14
Commonwealth Equity Services LLC Buys 31,177 Shares of Charles River Laboratories International, Inc. $CRL
defenseworld.net · Nov 13
Ariel Small Cap Value Q3 2026 Portfolio Activity
seekingalpha.com · Nov 13
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.
